Brought to you by 
AcelRx Pharmaceuticals nets $44.7mm in follow-on public offering
07 Jan 2013
Executive Summary
AcelRx Pharmaceuticals Inc. (sublingual treatments for breakthrough and acute pain) netted $44.7mm in a follow-on public offering of 14.4mm shares (including the overallotment)--up from the 10mm it originally planned--at $3.31. Proceeds will help the company prepare an NDA filing in Q3 2013 for lead candidate ARX01 (sufentanil delivered via the NanoTab system for moderate-to-severe postoperative pain).
Deal Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AcelRx Pharmaceuticals nets $44.7mm in follow-on public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice